Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Henry Meds vs REMEVi

Henry Meds
Graded #46

Higher grade

vs+3.799999999999997
REMEVi
Graded #70

Lower grade

The verdict

Henry Meds takes it — 77.3/100 to 73.5/100.

Henry Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A flat-fee compounded pioneer — simple, but priced at the higher end of the board now.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHenry Meds +15
72
57
Dose & formulationREMEVi +3
80
83
Clinical oversightREMEVi +6
80
86
Labs & monitoringHenry Meds +23
78
55
FulfillmentREMEVi +19
78
97
Contract termsHenry Meds +9
78
69
Henry Meds · left barREMEVi · right bar

The numbers

MetricHenry MedsREMEVi
WeighScore77.3/10073.5/100
GradeC+C
Scorecard rank#46#70
Semaglutide$249/mo$219/mo
Tirzepatide$349/mo$319/mo
CoverageMulti-stateAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Henry Meds

Graded #46 · C+

Strengths

  • Simple flat-fee model
  • Established brand
  • Both molecules

Where it loses points

  • Higher pricing than newer entrants
  • Compounded only
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard